Toronto, March 24, 2022 (BUSINESS WIRE) — In the year 2022, there will be an increase in the number of people living in Canada. New York-based Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) has announced that it is recruiting participants for a feasibility study using Kernel’s Kernel Flow quantitative neuroimaging technology to advance the development of “Psychedelic Therapeutics.” Wearing Kernel Flow while in an altered state of consciousness after taking ketamine is the focus of this study.
Participants will be given either a low dose of ketamine or a placebo while wearing the Kernel Flow headset, which is equipped with hi-tech sensors to record brain activity, and will report their experience using structured questionnaires and validated assessments during study visits and a follow-up. Prior to and following the administration of low-dose ketamine or placebo, brain activity will be monitored.
Also read: Superintendent Graham appointed to Pontotoc Technology Center
Cybin’s CEO, Doug Drysdale, said, “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantify information on a psychedelic experience.” “Until now, our understanding of what it means to have a psychedelic experience has been very subjective. To bridge the gap between bringing psychedelics to therapeutics and learning more about the advantages of these important molecules on brain activity and overall mental well-being, this study may lead to larger studies. “
Also read: Precision motor technology of Piezo Motion Now Available in Germany
